Research programme: anti-CLEVER-1 antibodies - Faron PharmaceuticalsAlternative Names: Clevegen®; FP-1115; FP-1302; FP-1304
Latest Information Update: 27 Jul 2016
At a glance
- Originator Faron Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action STAB1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
- Discontinued Inflammation